<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821651</url>
  </required_header>
  <id_info>
    <org_study_id>HOR-1</org_study_id>
    <nct_id>NCT01821651</nct_id>
  </id_info>
  <brief_title>Use of Standardized Diagnostic Imaging Data for Image Fusion in the Hybrid Operating Room</brief_title>
  <official_title>Use of Standardized Diagnostic Imaging Data (Computertomography, Angiography, Echocardiography) for Image Fusion in the Hybrid Operating Room</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
      Goal of the study is to investigate the potential benefit that transcatheter interventions&#xD;
      such as Transcatheter Aortic Valve Implantation (TAVI), MitraClip, Left Atrial Appendage&#xD;
      Closure and catheter Ablation can gain from multimodal image fusion techniques as they are&#xD;
      available in the Hybrid suite.&#xD;
&#xD;
      Both the HeartNavigator and the EchoNav aim at decreasing the exposure to radiation and&#xD;
      contrast agent, to shorten the operation time (efficacy), and to increase the quality of care&#xD;
      (safety).&#xD;
&#xD;
      This pilot study aims at observing these aims on a small patient population and a control&#xD;
      group.&#xD;
&#xD;
      Number of Subjects:&#xD;
&#xD;
      140 patients total in 6 groups:&#xD;
&#xD;
        -  MitraClip, Left Atrial Appendage Closure or catheter Ablation with EchoNav (20, lead-in&#xD;
           stage).&#xD;
&#xD;
        -  MitraClip randomized with EchoNav (25), MitraClip randomized without EchoNav (25).&#xD;
&#xD;
        -  TAVI with HeartNavigator lead in (10)&#xD;
&#xD;
        -  TAVI randomized with HeartNavigator (30), TAVI randomized without HeartNavigator (30).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical Device:&#xD;
&#xD;
      HeartNavigator: System for preoperative image-based assessment of aortic root geometry,&#xD;
      planning of transcatheter aortic valve implantation, and intraoperative C-Arm control.&#xD;
&#xD;
      EchoNav: System for intraoperative registration of 3D Echo images with X-ray fluoroscopy&#xD;
      images.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiation Dose (mSv) administered to each patient</measure>
    <time_frame>Day of intervention (day 1)</time_frame>
    <description>At the end of the procedure the recorded radiation-dose is assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the intervention (minutes)</measure>
    <time_frame>Day of intervention (day 1)</time_frame>
    <description>At the end of the procedure the skin-to-skin-time is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast agent dose (ml)</measure>
    <time_frame>Day of intervention (day 1)</time_frame>
    <description>At the end of the procedure the recorded contrast agent dose is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increased quality of care (EchoNav group)</measure>
    <time_frame>Discharge: 1 to 5 days after intervention</time_frame>
    <description>Usually 1 to 5 days after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Mitral Regurgitation (EchoNav group)</measure>
    <time_frame>Discharge: 1 to 5 days after intervention</time_frame>
    <description>Usually 1 to 5 days after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postinterventional transvalvular gradient</measure>
    <time_frame>Up to 7 days after intervention</time_frame>
    <description>Catheter-based direct measurement</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Heart Valve Diseases</condition>
  <arm_group>
    <arm_group_label>HeartNavigator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group with HeartNavigator-Software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control-group without HeartNavigator-Software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EchoNav</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group with EchoNav-Software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control-group without EchoNav-Software</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartNavigator</intervention_name>
    <description>Procedure with software</description>
    <arm_group_label>HeartNavigator</arm_group_label>
    <other_name>HeartNavigator, procedure with software</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EchoNav</intervention_name>
    <description>Procedure with software</description>
    <arm_group_label>EchoNav</arm_group_label>
    <other_name>EchoNav, procedure with software</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control-Group EN</intervention_name>
    <description>Procedure without software</description>
    <arm_group_label>Conrol</arm_group_label>
    <other_name>Compare to EchoNav-group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control-group HN</intervention_name>
    <description>Procedure without software</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Compare to HeartNavigator-group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Male and female patients over 18 years of age.&#xD;
&#xD;
          -  Ability and willingness to give informed consent.&#xD;
&#xD;
          -  Indication for TAVI, MitraClip, catheter ablation or percutaneous closure of the left&#xD;
             atrial appendage procedure performed in the hybrid OR suite.&#xD;
&#xD;
          -  Recent good quality CTA (TAVI patients only, no CTA needed for EchoNav).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Contraindications on ethical grounds,&#xD;
&#xD;
          -  Women who are pregnant or breast feeding,&#xD;
&#xD;
          -  Emergency cases,&#xD;
&#xD;
          -  Contraindication or known hypersensitivity to contrast media which is unresponsive to&#xD;
             pretreatment with steroids and antihistamines,&#xD;
&#xD;
          -  Known renal insufficiency (GFR &lt; 50 ml/min) and patient is not on chronic hemodialysis&#xD;
             (TAVI patients only, no contrast agent is necessary during MitraClip and transseptal&#xD;
             puncture),&#xD;
&#xD;
          -  Contraindications for transesophageal Echo (EchoNav patients only, TAVI is possible&#xD;
             without TEE and TEE is not needed for the HeartNavigator),&#xD;
&#xD;
          -  Known or suspected drug or alcohol abuse,&#xD;
&#xD;
          -  Enrollment into a clinical trial within last 4 weeks if overlapping enrolment is not&#xD;
             explicitly approved by ethics committee for the two trials,&#xD;
&#xD;
          -  Patient is unable or unwilling to cooperate with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volkmar Falk, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Cardiovascular Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon SÃ¼ndermann, MD</last_name>
    <email>simon.suendermann@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Volkmar Falk, Prof MD</last_name>
    <email>volkmar.falk@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Cardiovascular Surgery</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>MitraClip</keyword>
  <keyword>image modality</keyword>
  <keyword>echocardiography</keyword>
  <keyword>angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

